Today's edition · Saturday, November 21, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechNew Jersey

Health & TechPlainsboro, New Jersey

FDA approves a once-weekly growth hormone for children with Turner syndrome

Sogroya was approved for children 2.5 and older. In the phase 3 REAL8 trial, weekly dosing matched daily injections and spared families 313 injection days a year.

Verified · Source: HealioNov 20, 2026 · 1 min read
How to help
A small clear glass medicine vial
Illustrative photo of a glass medicine vial. This is not Sogroya, and no patients are shown. National Gallery of Art / Wikimedia Commons · Public domain

Read the original

The reporting lives at Healio. Our summary is checked against it, and we link it on every story.

The FDA approved Sogroya as the first once-weekly growth hormone for children with growth failure linked to Turner syndrome, Healio reported. The approval covers children 2.5 and older. It is based on the phase 3 REAL8 trial, in which weekly dosing matched daily injections. That schedule spares families 313 injection days a year.

Once a week is the new dosing. Daily injections are what the weekly shot matched in the trial. 313 days is the difference in injection days over a year. This is an approval based on that comparison, not a claim about every child's growth.

More good news

Other stories in the same neighborhood of kindness.